Pulmonary hypertension management starts with appropriately stratifying patients into risk groups and treating them accordingly. Hone your skills now!
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Pulmonary Hypertension Management: Practice Trends and Updates
Pulmonary hypertension management starts with appropriately stratifying patients into risk groups and treating them accordingly. Hone your skills now!
Live
Broadcast
1.00 available credits
Information
September 24, 2024
02:00 PM - 03:00 PM EDT
Online
Share
This live broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Share
Share
Share this program on:
Details
Presenters
Comments
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Vallerie McLaughlin, MD
Professor, Internal Medicine
University of Michigan
Ann Arbor, MIDr. McLaughlin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months.
Research: Aerovate, Altavant, Gossamer Bio, Janssen, Merck, SoniVie
Consulting fees: Aerami, Aerovate, Altavant, Bayer, Caremark, CorVista, Gossamer Bio, Janssen, Merck, United TherapeuticsVictor Moles, MD
Clinical Assistant Professor
University of Michigan
Ann Arbor, MIDr. Moles has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Janssen, Keros, Merck, Parexel
Consulting Fees: United TherapeuticsIoana Preston, MD
Associate Professor of Medicine
Tufts University School of Medicine
Boston, MADr. Preston has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Acceleron/Merck, Actelion/Janssen, Keros, Liquidia, Respira, United Therapeutics
Consulting fees: Acceleron/Merck, Actelion/Janssen, Aerovate, Gossamer, Keros, Liquidia, Respira, United TherapeuticsReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Katie Sheridan has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss how new agents and trial results within the pulmonary hypertension (PH) community will impact care moving forward
- Discuss how clinical endpoints are relative to outcome measures while managing patients with PH
- Understand how to mitigate adverse events while maximizing therapy for patients with PH
Target Audience
This activity has been designed to meet the educational needs of cardiologists and pulmonologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with pulmonary hypertension.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LL. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live and enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 contact hour/0.10 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-101-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, and Merck Sharp & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Comments
Recommended
Overview
Pulmonary hypertension management starts with appropriately stratifying patients into risk groups and treating them accordingly. Hone your skills now!
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Vallerie McLaughlin, MD
Professor, Internal Medicine
University of Michigan
Ann Arbor, MIDr. McLaughlin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months.
Research: Aerovate, Altavant, Gossamer Bio, Janssen, Merck, SoniVie
Consulting fees: Aerami, Aerovate, Altavant, Bayer, Caremark, CorVista, Gossamer Bio, Janssen, Merck, United TherapeuticsVictor Moles, MD
Clinical Assistant Professor
University of Michigan
Ann Arbor, MIDr. Moles has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Janssen, Keros, Merck, Parexel
Consulting Fees: United TherapeuticsIoana Preston, MD
Associate Professor of Medicine
Tufts University School of Medicine
Boston, MADr. Preston has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Acceleron/Merck, Actelion/Janssen, Keros, Liquidia, Respira, United Therapeutics
Consulting fees: Acceleron/Merck, Actelion/Janssen, Aerovate, Gossamer, Keros, Liquidia, Respira, United TherapeuticsReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Katie Sheridan has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss how new agents and trial results within the pulmonary hypertension (PH) community will impact care moving forward
- Discuss how clinical endpoints are relative to outcome measures while managing patients with PH
- Understand how to mitigate adverse events while maximizing therapy for patients with PH
Target Audience
This activity has been designed to meet the educational needs of cardiologists and pulmonologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with pulmonary hypertension.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LL. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live and enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.00 contact hour/0.10 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-101-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, and Merck Sharp & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+